120 related articles for article (PubMed ID: 8322461)
1. The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen.
Crowell EB; Higa GM
W V Med J; 1993 Jun; 89(6):233-5. PubMed ID: 8322461
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
3. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
Fierro MT; Bertero M; Novelli M; Appino A; Doveil GC; Colonna S; Bernengo MG
Melanoma Res; 1993 Apr; 3(2):127-31. PubMed ID: 8518551
[TBL] [Abstract][Full Text] [Related]
4. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for stage 4 melanoma: a three-year experience with cisplatin, DTIC, BCNU, and tamoxifen.
Reintgen D; Saba H
Semin Surg Oncol; 1993; 9(3):251-5. PubMed ID: 8516613
[TBL] [Abstract][Full Text] [Related]
7. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Del Prete SA; Maurer LH; O'Donnell J; Forcier RJ; LeMarbre P
Cancer Treat Rep; 1984 Nov; 68(11):1403-5. PubMed ID: 6541973
[No Abstract] [Full Text] [Related]
10. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
McClay EF; Mastrangelo MJ; Bellet RE; Berd D
Cancer Treat Rep; 1987 May; 71(5):465-9. PubMed ID: 3567970
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
[TBL] [Abstract][Full Text] [Related]
13. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.
Agarwala SS; Ferri W; Gooding W; Kirkwood JM
Cancer; 1999 May; 85(9):1979-84. PubMed ID: 10223239
[TBL] [Abstract][Full Text] [Related]
14. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
15. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Hofmann MA; Sterry W; Trefzer U
Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
[TBL] [Abstract][Full Text] [Related]
16. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
McClay EF; Mastrangelo MJ; Sprandio JD; Bellet RE; Berd D
Cancer; 1989 Apr; 63(7):1292-5. PubMed ID: 2920358
[TBL] [Abstract][Full Text] [Related]
17. A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine.
Saunders MP; Salisbury AJ; O'Byrne KJ; Souliotis VL; Varcoe SM; Talbot DC; Kyrtopoulos SA; Harris AL
Anticancer Res; 1997; 17(6D):4677-80. PubMed ID: 9494588
[TBL] [Abstract][Full Text] [Related]
18. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy in combination with laser coagulation or interstitial hyperthermia--effective combined therapy for disseminated skin melanoma].
Akimov MA; Gel'fond ML; Gershanovich ML; Barchuk AS
Vopr Onkol; 2003; 49(3):312-5. PubMed ID: 12926212
[TBL] [Abstract][Full Text] [Related]
20. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
Tessier MH; Mansat E; Legoux B; Litoux P; Dreno B
Ann Dermatol Venereol; 1996; 123(9):538-42. PubMed ID: 9615103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
